Routine assessment of ER, PR and HER2 status in pure DCIS is therefore a promising instrument that could facilitate the development of evidence-based and DCIS subtype-dependent guidelines, aiming to de-escalate therapy in low-risk patients. Here, ESR1 is linked to ductal breast carcinoma in situ.